摘要
目的分析人表皮生长因子受体-2(HER-2)阳性乳腺癌患者进行帕妥珠单抗联合曲妥珠单抗治疗的近期疗效观察和安全性。方法将2023年2月至2024年1月收治的河南省南阳市肿瘤医院西药科HER-2阳性乳腺癌患者104例按随机数字表法分为对照组(52例)和研究组(52例)。对照组进行曲妥珠单抗治疗,研究组进行帕妥珠单抗联合曲妥珠单抗治疗,治疗周期为4个疗程。对比对照组、研究组治疗4个疗程后疗效,治疗前后微小RNA-375(miR-375)、糖类抗原153(CA153)、癌胚抗原(CEA)、糖类抗原125(CA125)水平及社会功能、认知功能、躯体功能、整体健康评分,以及治疗期间肝功能损害、心悸、胃肠反应、乏力、心脏毒性、周围神经毒性、骨髓抑制发生情况。结果对照组、研究组治疗后客观缓解率为19.2%(10/52)、36.5%(19/52),研究组比对照组更高(χ^(2)=3.873,P<0.05)。治疗后相较于治疗前,2组患者miR-375、CA153、CEA、CA125水平明显降低,研究组相较于对照组更低(t=9.760、2.764、11.147、5.402,P均<0.05)。治疗后相较于治疗前,2组患者社会功能、认知功能、躯体功能、整体健康评分升高,研究组相较于对照组更高(t=2.019、2.738、5.086、2.826,P<0.05)。对比对照组与研究组患者治疗期间的肝功能损害、心悸、胃肠反应、乏力、心脏毒性、周围神经毒性、骨髓抑制发生率,差异无统计学意义(χ^(2)=0.000、0.088、0.231、0.205,P>0.05)。结论帕妥珠单抗联合曲妥珠单抗治疗HER-2阳性乳腺癌患者可使临床疗效得到提升,降低肿瘤标志物水平,阻止疾病进展,改善患者生活质量,安全性良好。
Objective To analyze the short-term efficacy and safety of patuzumab combined with trastuzumab in the treatment of human epidermal growth factor receptor-2(HER-2)positive breast cancer.Methods A total of 104 HER-2 positive breast cancer patients admitted to the Department of Western Medicine of Nanyang Cancer Hospital from February 2023 to January 2024 were divided into the control group(52 cases)and the study group(52 cases)according to the random number table method.The control group received trastuzumab treatment,while the study group received pertuzumab combined with trastuzumab treatment,with a treatment period of 4 courses.Comparing the efficacy between the control group and the study group after 4 cours-es of treatment.Specifically,evaluated the levels of microRNA-375(miR-375),carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA),and carbohydrate antigen 125(CA125)before and after treatment.Additionally,assessed the scores for social function,cognitive function,physical function,and overall health.Furthermore,monitored the occurrence of liver function impairment,palpitations,gastrointestinal reactions,fatigue,cardiotoxici-ty,peripheral neurotoxicity,and bone marrow suppression during treatment.Results The objective remission rates of the control group and the study group after 4 treatment courses were 19.2%(10/52)and 36.5%(19/52),respectively.The study group had a higher rate than the control group(χ^(2)=3.873,P<0.05).After treatment,com-pared with before treatment,the levels of miR-375,CA153,CEA,and CA125 in both groups of patients signifi-cantly decreased after treatment,and the levels in the study group were lower than those in the control group(t=9.760,2.764,11.147,5.402,P<0.05).After treatment,compared with before treatment,the social function,cogni-tive function,physical function,and overall health scores of the two groups of patients were significantly increased,and the study group had higher scores than the control group(t=2.019,2.738,5.086,2.826,P<0.05).There was no statistically signific
作者
程林
顾德伦
Cheng Lin;Gu Delun(Department of Western Medicine,Nanyang Cancer Hospital,Nanyang,Henan 473000,China)
出处
《中国药物与临床》
CAS
2024年第17期1142-1145,共4页
Chinese Remedies & Clinics
关键词
表皮生长因子
乳腺肿瘤
治疗结果
Epidermal growth factor
Breast neoplasms
Treatment outcome
